Table 2.
Combination index values for combined treatment of docetaxel and ABT-263 in A549 and H727
| Docetaxel (nM) | ABT-263 (µM) | A549 | H727 | ||||
|---|---|---|---|---|---|---|---|
| Viable cell (%) | CI | Degree of synergism/antagonism | Viable cell (%) | CI | Degree of synergy/antagonism | ||
| 60.00 | 6.00 | 1.2 ± 0.2 | 0.004 | Very strong synergistic | 2.4 ± 0.2 | 0.118 | Strong synergistic |
| 20.00 | 2.00 | 1.4 ± 0.4 | 0.001 | Very strong synergistic | 6.5 ± 1.7 | 0.092 | Very strong synergistic |
| 6.67 | 0.67 | 13.4 ± 1.8 | 0.010 | Very strong synergistic | 49.1 ± 2.8 | 0.356 | Moderate synergistic |
| 2.22 | 0.22 | 32.8 ± 2.1 | 0.069 | Very strong synergistic | 75.7 ± 2.5 | 0.445 | Moderate synergistic |
| 0.74 | 0.07 | 57.5 ± 1.9 | 0.805 | Moderate synergistic | 94.5 ± 3.4 | 1.225 | Moderate antagonistic |
A549 or H727 cells were treated with different concentrations of docetaxel, ABT-263 and their respective combinations as indicated. The percentage of viable cell numbers was quantified by MTT assay. CI values were calculated using the CompuSyn, Inc. software program